IDO1 and myelodysplastic syndrome: Combinatorial targeting of IDO immunosuppressive role with ICB has been clinically tested and has emerged as promising cancer therapy for a variety of cancer types (e.g., melanoma, ovary, breast, myelodysplastic syndrome (MDS)) [56].